Safety and Pharmacokinetic Study of IT-141 in Monotherapy in Patients With Advanced Cancer
Status:
Terminated
Trial end date:
2019-11-26
Target enrollment:
Participant gender:
Summary
IT141 is a novel nanoparticle formulation of SN-38, the active metabolite of irinotecan, and
is intended to deliver more drug to the tumor with reduced toxicity on normal tissues. The
study is designed to determine the maximum tolerated dose (MTD) of IT-141, and to investigate
pharmacokinetic (PK) parameters and possible pharmacodynamics (PD) relationships. Patients
will also be monitored for any response to therapy.